Literature DB >> 20956192

The arterial load in pulmonary hypertension.

N Saouti1, N Westerhof, P E Postmus, A Vonk-Noordegraaf.   

Abstract

The anatomical differences between the pulmonary and systemic arterial system are the main cause of the difference in distribution of compliance. In the pulmonary arterial system compliance is distributed over the entire arterial system, and stands at the basis of the constancy of the RC-time. This distribution depends on the number of peripheral vessels, which is ∼8-10 times more in the pulmonary system than the systemic tree. In the systemic arterial tree the compliance is mainly located in the aorta (80% of total compliance in thoracic-abdominal aorta). The constant RC-time in the pulmonary bed results in proportionality of systolic and diastolic pressure with mean pressure and, in turn, in the constant ratio of oscillatory and mean power.

Entities:  

Mesh:

Year:  2010        PMID: 20956192     DOI: 10.1183/09059180.00002210

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  54 in total

1.  Pulmonary Arterial Stiffness: Toward a New Paradigm in Pulmonary Arterial Hypertension Pathophysiology and Assessment.

Authors:  Michal Schäfer; Cynthia Myers; R Dale Brown; Maria G Frid; Wei Tan; Kendall Hunter; Kurt R Stenmark
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

2.  Noninvasive pulmonary artery pressure monitoring by EIT: a model-based feasibility study.

Authors:  Martin Proença; Fabian Braun; Josep Solà; Jean-Philippe Thiran; Mathieu Lemay
Journal:  Med Biol Eng Comput       Date:  2016-09-17       Impact factor: 2.602

Review 3.  Right ventricular afterload and the role of nitric oxide metabolism in left-sided heart failure.

Authors:  Matthias Dupont; W H Wilson Tang
Journal:  J Card Fail       Date:  2013-09-05       Impact factor: 5.712

4.  Effect of acute arteriolar vasodilation on capacitance and resistance in pulmonary arterial hypertension.

Authors:  John H Newman; Evan L Brittain; Ivan M Robbins; Anna R Hemnes
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

5.  Vascular stiffening in pulmonary hypertension: cause or consequence? (2013 Grover Conference series).

Authors:  Wei Tan; Krishna Madhavan; Kendall S Hunter; Daewon Park; Kurt R Stenmark
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

6.  Location of embolization affects patency after coil embolization for pulmonary arteriovenous malformations: importance of time-resolved magnetic resonance angiography for diagnosis of patency.

Authors:  Masashi Shimohira; Hiro Kiyosue; Keigo Osuga; Hideo Gobara; Hiroshi Kondo; Tetsuro Nakazawa; Yusuke Matsui; Kohei Hamamoto; Tomoya Ishiguro; Miyuki Maruno; Koji Sugimoto; Masamichi Koganemaru; Akira Kitagawa; Koichiro Yamakado
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

Review 7.  Methods for measuring right ventricular function and hemodynamic coupling with the pulmonary vasculature.

Authors:  Alessandro Bellofiore; Naomi C Chesler
Journal:  Ann Biomed Eng       Date:  2013-02-20       Impact factor: 3.934

8.  Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension: How can patients be better selected?

Authors:  Juan C Grignola; Enric Domingo
Journal:  World J Cardiol       Date:  2013-03-26

9.  Reduced haemodynamic coupling and exercise are associated with vascular stiffening in pulmonary arterial hypertension.

Authors:  Alessandro Bellofiore; Eric Dinges; Robert Naeije; Hamorabi Mkrdichian; Lauren Beussink-Nelson; Melissa Bailey; Michael J Cuttica; Ranya Sweis; James R Runo; Jon G Keevil; Christopher J Francois; Sanjiv J Shah; Naomi C Chesler
Journal:  Heart       Date:  2016-08-26       Impact factor: 5.994

10.  A non-invasive assessment of cardiopulmonary hemodynamics with MRI in pulmonary hypertension.

Authors:  Octavia Bane; Sanjiv J Shah; Michael J Cuttica; Jeremy D Collins; Senthil Selvaraj; Neil R Chatterjee; Christoph Guetter; James C Carr; Timothy J Carroll
Journal:  Magn Reson Imaging       Date:  2015-08-14       Impact factor: 2.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.